Adial Pharmaceuticals received a notice from Nasdaq on August 18, 2026, indicating it no longer satisfies the minimum stockholders' equity requirement of $2.5 million for continued listing under Rule 5550(b)(1). The company also lacks alternative quantitative standards regarding market value or net income. Adial has until October 2, 2026, to submit a compliance plan and may seek an extension of up to 180 days if the plan is accepted. The firm anticipates regaining compliance by converting its Series A Non-Voting Convertible Preferred Stock upon shareholder approval at the 2026 Annual Meeting. Adial Pharmaceuticals operates in the biopharmaceutical industry, developing treatments for central nervous system disorders.

Adial Pharmaceuticals reported second quarter 2026 financial results and announced the completed acquisition of Azora Therapeutics, adding AT177, an oral AhR agonist for ulcerative colitis, to its pipeline. The company closed the initial $32 million tranche of a $64 million private placement, which included the conversion of $5.5 million in notes. Cash and cash equivalents rose to $28.7 million from $4.6 million at the end of March 2026. The quarter ended June 30, 2026, resulted in a net loss of $52.0 million, or $(11.25) per share, driven primarily by a $46.2 million non-cash charge for acquired in-process research and development expenses related to the Azora transaction. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory diseases.

Adial Pharmaceuticals announced that its current President and CEO Cary Claiborne and CFO Vinay Shah will be terminated effective after the September 17, 2026 Annual Meeting if specific stockholder proposals are approved. Upon termination, they will receive severance per their employment agreements. Chief Development Officer Matthew Davidson is slated to become President and CEO, with a new CFO to be appointed. The filing also sets the annual meeting date for September 17, 2026, and establishes August 23, 2026 as the deadline for stockholder proposals. This corporate governance restructuring involves significant leadership changes contingent on shareholder approval at an upcoming vote. Adial Pharmaceuticals operates in the pharmaceutical industry, focusing on developing treatments for gastrointestinal disorders.

Adial Pharmaceuticals, Inc. filed an amendment to its Form 8-K to include the historical and pro forma financial statements required for its acquisition of Azora Therapeutics, Inc., which closed on June 11, 2026. In exchange for all shares of Azora, Adial issued 437,421 common shares and Series A Non-Voting Convertible Preferred Stock convertible into 12,930,617 common shares. Concurrently, Adial raised approximately $26.8 million in gross proceeds from a PIPE financing by issuing pre-funded warrants to purchase 9,749,345 shares at $2.7489 per warrant. The transaction also involved the extinguishment of $5.5 million of Azora's convertible promissory notes via exchange agreements for additional warrants. Adial Pharmaceuticals operates in the biopharmaceutical industry.

On June 11, 2026, Adial Pharmaceuticals acquired Azora Therapeutics. Adial issued 437,474 shares of Common Stock and 12,930.617 shares of Series A Non-Voting Convertible Preferred Stock (convertible at 1,000:1) to Azora stockholders. Concurrently, Adial entered into a PIPE financing for $26.8 million in initial pre-funded warrants, with an additional $26.8 million available via milestone closings. Adial also retired $5.5 million of Azora convertible notes via an exchange for pre-funded warrants. Matt Davidson was appointed as a Director and Chief Development Officer, and Wendy Young was appointed as a Director. Tony Goodman resigned as a Director. The company will seek stockholder approval for various proposals, including a potential reverse stock split to maintain Nasdaq compliance. Adial is a pharmaceutical company that develops therapeutic products.